Dive into the pressing issue of “NASH or Diabesity: Which Comes First?” on 29th Sep 2023. Unveil insights from top experts, explore the intertwining relation of diabetes and obesity, and the NAFLD/NASH epidemic.
The landscape of Non-Alcoholic Fatty Liver Disease (NAFLD) and its progression, NASH, against the backdrop of the diabetes and obesity epidemic, often termed “diabesity”, is evolving rapidly.
Attending this event will give participants a front-row seat to cutting-edge discussions surrounding the intertwined relationships between these conditions. Eminent professionals with diverse and rich experiences in the field, will delve deep into topics that shape the current understanding of NASH and diabesity.
From the broader context of the NAFLD/NASH epidemic in the diabesity environment to presentations like China’s fatty liver crisis, this event promises holistic coverage.
Furthermore, the arena of treatment modalities and monitoring mechanisms for NAFLD/NASH in the context of diabetes and obesity is vast and continually advancing.
This event stands as a beacon for those wishing to be at the forefront of such discussions, arming attendees with the latest research, treatment trends, and real-world implications.
Whether you’re a healthcare professional, a researcher in the field, or a medical student, this webinar is an invaluable opportunity to expand your horizons, network with the best in the business, and potentially shape your future endeavors in the domain.
Meet the Thought Leaders Shaping the Future of NASH and Diabesity.
Professor, Department of Gastroenterology & Hepatology Antwerp University Hospital
Prof. Dr. Sven Francque obtained his MD at the University of Antwerp, Belgium, in 1994 and was subsequently trained in internal medicine and in gastroenterology and hepatology at the Antwerp University Hospital, Belgium and at the Department of Hepatology of the Beaujon hospital, Clichy, France.
He has a long-standing interest and expertise in non-alcoholic fatty liver disease and conducted basic research focusing on the vascular changes in steatosis and their contribution to disease progression and leading to his PhD in 2011.
His research unit continues to study pathophysiological mechanisms of NASH, with a sustained focus on vascular mechanisms in early NAFLD as well as on the adipose tissue-liver interaction.
He is also conducting clinical research and his unit is partner in several research consortia supported by the European Commission and by the Innovative Medicines Initiative with a focus on NASH pathophysiology (with a focus on inter-organ cross-talk and the link with metabolism (especially PPARs), biomarker research and hepatocellular carcinoma.
His clinical trial unit has participated from the early days of clinical trials in NASH in many clinical trials in the field. Prof. Francque is a scientific committee member involved in the design of several phase 2 and current phase 3 trials in NAFLD and is national/international lead PI of several of these trials.
He is also president of the scientific committee of the PanNASH Initiative and member of the scientific committee of the NASH Education Program. He is author/co-author of over 200 papers in peer-reviewed journals and authored several book chapters on NAFLD. He is editor of JHep Reports, the open-access journal of the European Association for the Study of the Liver.
He is Educational Councillor-elect on the EASL Governing Board. He is senior clinical researcher for the Research Fund of the Flemish government.
He is currently chairman of the Department of Gastroenterology and Hepatology of the University Hospital Antwerp and senior full professor of medicine at the Faculty of Medicine and Health Sciences of the University of Antwerp.
He is scientific coordinator of the Belgian Week of Gastroenterology, the Belgian national gastroenterology and hepatology research meeting. He coordinated the Belgian guidelines on NAFLD and the EASL Patient NAFLD Guideline.
Professor, Faculty of Medicine, University of Southampton, UK
Chris Byrne trained as a physician-scientist in the UK and USA; at Cardiff, Cambridge and Stanford Universities undertaking a PhD studying liver lipid metabolism.
Chris Byrne is Professor of Endocrinology & Metabolism at the University of Southampton and Consultant Physician at University Hospital Southampton, with expertise in dyslipidaemias, metabolic liver disease and type 2 diabetes. Chris Byrne is a Principal Investigator within the Southampton National Institute for Health and Care Research (NIHR), Southampton Biomedical Research Centre.
Chris Byrne was the UK Diabetologist advisor to the NICE non-alcoholic fatty liver disease (NAFLD) Guidelines (ng49) in 2016; and recipient of the Dorothy Hodgkin award in 2012 and the Banting Memorial lecture award in 2022 from Diabetes UK.
The Banting Memorial Lecture is the highest award bestowed by Diabetes UK ‘to a person internationally recognised for their eminence in the field of diabetes’. In 2022 Chris Byrne was a ‘Clarivate’ ‘highly cited researcher’ (top 0.1% of global scientists) and in 2023 was ranked 5th by ‘Expertscape’ amongst global researchers for research output in NAFLD over the previous decade. Chris Byrne’s research (>450 peer-reviewed publications, including book chapters and three books) focusses on different aspects of NAFLD: including aetiology, pathogenesis, consequences and treatment.
M.D., F.A.C.P., F.A.C.E., Professor of Medicine Chief, Division of Endocrinology, Diabetes and Metabolism at The University of Florida at Gainesville, USA
Dr. Cusi is a Professor of Medicine and Chief of the Division of Endocrinology, Diabetes and Metabolism at The University of Florida at Gainesville (2011-present). He is also a faculty and researcher at the Endocrinology, Diabetes and Metabolism Division at the Veterans Administration Medical Center at Gainesville, Florida, USA.
He received his medical degree, did his internal medicine residency in Buenos Aires, Argentina, and completed a fellowship in Endocrinology, Diabetes and Metabolism at Baylor College of Medicine, Houston, Texas. He moved to San Antonio, Texas (1992) to work on the role of defects in insulin secretion and insulin resistance to the development of type 2 diabetes mellitus (T2DM), as well as on complications associated with T2DM.
He later focused on the relationship and underlying mechanisms of nonalcoholic fatty liver disease (NAFLD) in T2DM and its impact on dyslipidemia, diabetes control and cardiovascular disease.
Dr. Cusi has contributed to the field on the underlying mechanisms of NAFLD in obesity and diabetes and published the first RCT on pioglitazone for NASH for patients with prediabetes or T2DM (Belfort et al, NEJM 2006). This was followed by a recent long-term study confirming its value in this population (Cusi et al., Annals Intern Med 2016). Dr Cusi’s current work at the University of Florida centres on discovering the mechanism(s) leading to NASH and searching for novel treatments.
Dr Cusi has published more than 150 original articles, reviews and book chapters in a broad spectrum of peer-reviewed journals, such as the New England Journal of Medicine, Annals of Internal Medicine, Proceeding of the National Academy of Science, Journal of Clinical Investigation, Diabetes, Diabetes Care, J Clinical Endocrinology and Metabolism, American Journal of Physiology, Hepatology, Gastroenterology and others. He is an associate editor and reviewer for many journals in the fields of endocrinology, metabolism, diabetes and liver disease.
He is a frequently invited lecturer to national and international meetings on the role of obesity and NAFLD in T2DM. He is a member of the NIH Clinical and Integrative Diabetes and Obesity (CIDO) study section and contributed to the panel of the 2012 and 2017 NASH guidelines of the American Association for the Study of Liver Diseases. In 2015 Dr Cusi received two prestigious awards from the University of Florida, the Exemplary Teacher Award and the Clinical Research Award for outstanding achievement, research discovery, and productivity from the College of Medicine.
MD, PhD, Professor and Director of Department of Gastroenterology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Professor Jian-Gao Fan stands tall as a stalwart in the field of hepatology, particularly for his profound contributions to understanding fatty liver diseases. Currently serving as the Editor-in-Chief of the reputable Chinese Journal of Practical Hepatology, his editorial role speaks volumes about his expertise and discerning perspective in the domain of liver health.
Leading the Committee on Fatty Liver Diseases of the Chinese Physicians’ Association as its president, Professor Fan has been instrumental in shaping guidelines, fostering research, and driving awareness about fatty liver conditions in China. His role in these pivotal positions underscores his commitment to advancing the scientific understanding of liver diseases and championing better patient outcomes.
Between 2010 and 2022, Professor Fan co-chaired the Biennial Shanghai International Forum on Digestive Diseases, a prestigious platform that brings together international experts to discuss and deliberate on pressing issues surrounding digestive health. His leadership in this forum has been instrumental in fostering collaboration, promoting groundbreaking research, and advancing therapeutic interventions in digestive diseases.
But perhaps one of the most telling aspects of his esteemed career is his recognition as a sought-after speaker on global stages. Professor Fan has been invited to impart his knowledge and share his insights in over 20 countries and regions. This global acknowledgment is a testament to his unparalleled expertise and his capability to bridge research findings with real-world clinical applications.
In sum, Professor Jian-Gao Fan’s illustrious career and unyielding dedication make him an invaluable asset to any discourse on liver diseases and beyond. His vast experiences and pioneering work promise deep insights and meaningful discussions for all attendees.
Attendance is free